PLSE Stock — Pulse Biosciences, Inc.

Up next

Next earnings call

Nov 2, 2026 Est · unconfirmed · in 7 wks

Latest filing: 10-Q

filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$1.19M

Trailing 12 months

Net income (TTM)

−$80.06M

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

-7,007.8%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-1.6%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+25.5%

Year over year · more shares

Price change (1Y)

+251.7%

Trailing year

Short interest

4.4%

Latest settlement · 7.9 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 6, 2026

Q2 FY26

TL;DR. Pulse Biosciences reported accelerated NANOPULSE-AF pivotal IDE enrollment, surpassing the halfway point with a confirmed early Q4 completion target even after expanding enrollment to 164 patients, while strengthening the balance sheet to $101.6 million via a $57.5 million ATM raise, though quarterly net loss widened to $24.7 million on $0.4 million in product revenue.

Bullish

+ NANOPULSE-AF pivotal IDE enrollment surpassed the halfway point with over 82 evaluable patients, and the company reiterated an early Q4 completion target even after expanding enrollment to 164 patients.
+ Strong EU feasibility data showed 100% freedom from AF at 6 months and 96% at 12 months with a 1.7% serious adverse event rate, supporting a CE Mark submission for the catheter in the second half of 2026.
+ Surgical clamp EU feasibility showed 94% pulmonary vein isolation success at 3 months, with CE Mark filing for the nPulse Cardiac Surgical System on schedule before the end of 2026.

Bearish

− GAAP net loss widened to $24.7 million from $19.2 million in the prior year period, with quarterly operating cash use of $18.7 million.
− Product revenue remained minimal at $434,000 in Q2 2026 with the company still in a 'disciplined launch focused on clinical and market development.'
− GAAP costs and expenses increased $5.4 million year-over-year to $25.7 million, and the company guided quarterly non-GAAP operating expenses to 'remain in this range' going forward.
− Total non-GAAP net loss widened to $19.4 million from $13.7 million in the prior year period.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Limited Quant / Vol Very High

Market backdrop VIX 15.8 · calm Equity put/call 0.58

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +114%

above

Price vs 50-day avg +33%

above

RSI (14) 63

neutral

MACD trend Negative

52-week position 96%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +18%

trailing

6-month return +140%

trailing

YTD return +287%

this year

Relative strength +122%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $40 › 200d $25 — 50d above 200d

Institutional flow Accumulating

+10% holders QoQ · +21 funds added

Insider flow Accumulating

Net +$199.9K over 90 days · 0% sells

Short interest Rising

4.38% of float · ▲ +12.9% MoM · 7.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

106 holders — near 3-yr high, broad support

Squeeze score 75

high risk · 0–100

Fundamentals

Limited

Not enough data for a confident read.

Quant / Vol

risk profile

Very High

Volatility 89%

annualized · 1-yr

Max drawdown −37%

past year

ATR 7.4%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy

1 · 3 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+114% Bullish

Price vs 50-day avg

+33% Bullish

RSI (14)

63 Neutral

MACD trend

Negative Bearish

52-week position

96% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $40 › 200d $25 — 50d above 200d

Institutional flow Accumulating

+10% holders QoQ · +21 funds added

Insider flow Accumulating

Net +$199.9K over 90 days · 0% sells

Short interest Rising

4.38% of float · ▲ +12.9% MoM · 7.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

106 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $13 Now $53 · 96% Range high $55

vs 200-day avg +114% vs 50-day avg +33%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Instruments & Supplies — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
PLSE Pulse Biosciences, Inc. this stock	$3.79B	+286.8%	—	—	4.4%
ISRG Intuitive Surgical Inc	$130.41B	-34.8%	+20.5%	42.4	2.2%
BDX Becton Dickinson & Co	$48.44B	—	+8.2%	—	3.9%
MDLN Medline Inc.	$42.77B	-22.5%	+11.5%	—	3.0%
ALC Alcon Inc	$31.92B	-16.2%	+10.5%	—	3.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

106

% held: 15.1%
Net QoQ: +2.9M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

113

View

Short & Settlement

Short Interest Rising

Shares short

3.1M

Days to cover: 7.9d
Change: +355.4K sh

View

Short Volume

Short vol %

50%

As of: Sep 11, 2026

Short Total

View

Fails to Deliver

FTD shares

1.1K

Value: $47.8K
As of: Aug 12, 2026

View

Off-Exchange

Off-exchange %

44.5%

Week of: Aug 3, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net buying

Net (90d)

+$199.9K

Buyers / Sellers: 1 / 0

Buyers Sellers

View

Financials

Revenue (FY)

$350.0K

Net income (FY): $-72.8M

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Aug 11, 2026
This year: 35

View

Proposed Sales

Value

$1.3M

Shares: 50.0K
Filed: Feb 12, 2026

View

Exempt Offerings

Offering

$50.0M

Filed: Jul 9, 2021

View

Earnings & Events

Earnings Calls

Last call

Aug 11, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
PLSE	-2.9%	+18.2%	+140.3%	+5.5%	+286.8%
SPY	-1.2%	-1.8%	+17.8%	-0.4%	+12.1%
vs SPY	-1.8%	+20.0%	+122.5%	+5.9%	+274.7%

PLSE · Pulse Biosciences, Inc.

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance